PI3K Inhibitor Increased Radiosensitizing Effect of PARP Inhibitor in BRCA-Proficient Triple Negative Breast Cancer Cells

被引：0
|
作者：
Kim, I. A. [1 ,2 ]
Jang, N. Y. [3 ]
Kim, D. H. [2 ]
Cho, B. J. [4 ]
Choi, E. J. [2 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Med Sci Res Inst, Songnam, South Korea
[3] Seoul Natl Univ, Grad Sch Med, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Med Sci Res Inst, Songnam, South Korea
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1912
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3337
引用
收藏
页码：E533 / E534
页数：2
相关论文
共 50 条
  • [31] Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer
    Hillis, Alissandra L.
    Toker, Alex
    CANCER CELL, 2020, 38 (04) : 441 - 443
  • [32] Preclinical activity of INK128, a TORC1/2 inhibitor, in triple negative breast cancer: A combination of PARP inhibitor with PI3K-mTOR pathway-targeted inhibitor
    Leyland-Jones, Brian
    Wu, Hui
    Sun, Yuliang
    Rommel, Christian
    Yi, Liu
    De, Pradip
    Dey, Nandini
    CANCER RESEARCH, 2012, 72
  • [33] PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer
    Ibrahim, Yasir H.
    Garcia-Garcia, Celina
    Serra, Violeta
    Scaltriti, Maurizio
    Juric, Dejan
    Anton, Pilar
    Guzman, Marta
    Cozar, Patricia
    Aura, Claudia
    Jimenez, Jose
    Rubio, Isabel
    Perez, Jose
    Balmana, Judith
    Baselga, Jose
    CANCER RESEARCH, 2012, 72
  • [34] Targeting the PI3K Pathway Enhances the Effect of PARP-1 Inhibition in BRCA1 Deficient Breast Cancer Cells
    Kimbung, S.
    Aaltonen, K.
    Gruvberger-Saal, S.
    Berglund, P.
    Hedenfalk, I.
    CANCER RESEARCH, 2010, 70
  • [35] Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
    Al-Ejeh, Fares
    Shi, Wei
    Miranda, Mariska
    Simpson, Peter T.
    Vargas, Ana Cristina
    Song, Sarah
    Wiegmans, Adrian P.
    Swarbrick, Alex
    Welm, Alana L.
    Brown, Michael P.
    Chenevix-Trench, Georgia
    Lakhani, Sunil R.
    Khanna, Kum Kum
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (06) : 913 - 921
  • [36] Combination treatment of PARP inhibitor, BMN 673 and DNMT inhibitor, Azacytidine: A potential therapy for BRCA negative and positive, triple negative breast cancers
    Chowdhury, Khadiza
    Lapidus, Rena G.
    Choi, Eun Yong
    Baylin, Stephen
    Rassool, Feyruz V.
    CANCER RESEARCH, 2015, 75
  • [37] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2023, 84 (06)
  • [38] Sigma-2 ligands sensitize triple negative breast cancer cells to PARP inhibitor treatment
    Zeng, Chenbo
    Mankoff, Julia
    Mach, Robert H.
    CANCER RESEARCH, 2015, 75
  • [39] Targeting PI3K/AKT pathway in triple-negative breast cancer
    Delaloge, Suzette
    DeForceville, Louise
    LANCET ONCOLOGY, 2017, 18 (10): : 1293 - 1294
  • [40] Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
    Prvanovic, Mirjana
    Nedeljkovic, Milica
    Tanic, Nasta
    Tomic, Tijana
    Terzic, Tanja
    Milovanovic, Zorka
    Maksimovic, Zlatko
    Tanic, Nikola
    LIFE-BASEL, 2021, 11 (11):
12345